Delhi High Court rejects plea to halt HPV vaccine administration

• The Delhi High Court refused to stop the administration of the HPV vaccine to adolescent girls.
• Over 55 lakh HPV vaccines have been administered till date with only 120 cases of minor side effects reported.
• The government assured the court that the vaccine is safe and provided data showing its efficacy.
• The court has not ruled out the possibility of considering the justification for introducing the vaccine in future proceedings.

There may not be long-term benefit, but there is no immediate harm

The Delhi High Court has turned down a plea to stop the administration of the Human Papillomavirus (HPV) vaccine, Gardasil, to adolescent girls. The decision was made after the government assured the court that the vaccine is safe and provided data showing its efficacy. According to the government's submissions, over 55 lakh HPV vaccines have been administered till date, with only 120 cases of minor side effects reported.

The High Court's order was passed while hearing a Public Interest Litigation (PIL) filed by gynaecologist Dr. Sujata Mittal and fitness influencer Jitendra Chauksey, who raised questions over the data, efficacy, and requirement of the vaccine. The court had previously expressed its concern about the issue, asking for the government's response in a hearing on July 22. Additional Solicitor General (ASG) Chetan Sharma and Central Government Standing Counsel (CGSC) Ashish Dixit appeared for the government to present relevant data before the Court.

The Delhi High Court's refusal to halt the administration of the HPV vaccine is a significant development in the ongoing debate over its safety and efficacy. While the court has not ruled out the possibility of considering the justification for introducing the vaccine in future proceedings, it has given the green light for its continued use. This decision has implications for healthcare professionals, policymakers, and individuals who have been vaccinated or are considering vaccination.

Lawyers should note that the Delhi High Court has refused to stop the administration of the HPV vaccine, but may consider the justification for introducing it in future proceedings. Compliance officers should be aware that this development does not affect the existing regulatory framework for vaccination programs.

Source: Original reporting via The Hindu